Abstract Details

Title Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-lowering Antisense Oligonucleotide, in Patients With Alzheimer Disease

Topic Aging and Dementia

Presentation(s) S2 - (-)

Poster/Presentation
Number 006

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Laurence Mignon, PhD (Ionis Pharmaceuticals, Inc) PRESENTER	No disclosure on file
Holly Kordasiewcz	No disclosure on file
Roger M. Lane, MD, MPH (Ionis Pharmaceuticals)	No disclosure on file
Anne Smith (Isis Pharmaceuticals)	Anne Smith has received personal compensation for serving as an employee of Ionis Pharmaceuticals.
Timothy M. Miller, MD, PhD (Washington University)	Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ionis Pharmaceuticals. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Disarm Therapeutics. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen IDEC. Dr. Miller has received intellectual property interests from a discovery or technology relating to health care. Dr. Miller has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file
Eric Swayze, PhD (Isis Pharmaceuticals)	No disclosure on file
	No disclosure on file
	No disclosure on file
Frank Bennett, PhD	No disclosure on file